Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Indivior Pharmaceuticals, Inc. - Common Stock (NQ:INDV)

38.82 +0.15 (+0.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,687,044
Open	38.83
Bid (Size)	36.40 (1,000)
Ask (Size)	39.36 (300)
Prev. Close	38.67
Today's Range	38.08 - 38.91
52wk Range	21.69 - 42.81
Shares Outstanding	128,000,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Supernus Pharmaceuticals Stock Topped the Market Today ↗

August 03, 2026

It's effecting a "merger of equals" with a peer.

Via The Motley Fool

Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders

August 03, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Performance

YTD	+8.6%	+8.6%
1 Month	-5.1%	-5.1%
3 Month	-1.7%	-1.7%
6 Month	+12.9%	+12.9%
1 Year	+76.1%	+76.1%

More News

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 03, 2026

From Halper Sadeh LLC

Via Business Wire

Indivior Q2 Earnings Call Highlights ↗

August 03, 2026

Via MarketBeat

INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score ↗

July 17, 2026

Via Chartmill

Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen ↗

June 02, 2026

Via Chartmill

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge ↗

April 30, 2026

Via Chartmill

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

August 03, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

August 03, 2026

From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.

Via GlobeNewswire

Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

July 23, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? ↗

June 14, 2026

Via The Motley Fool

Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential ↗

April 21, 2026

Via Chartmill

What to Know About This Fund's $74.8 Million Indivior Sale ↗

May 30, 2026

Via The Motley Fool

Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200% ↗

May 30, 2026

Via The Motley Fool

What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally ↗

May 29, 2026

Via The Motley Fool

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

May 20, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior to Participate in Upcoming Investor Conferences

May 14, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally ↗

May 11, 2026

Via The Motley Fool

Indivior Announces $175 Million Accelerated Share Repurchase

May 04, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior (INDV) Q1 2026 Earnings Transcript ↗

May 01, 2026

Via The Motley Fool

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

April 30, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

April 24, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

April 16, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

April 09, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

March 31, 2026

From Indivior Pharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Indivior Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Indivior Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Indivior Pharmaceuticals, Inc. - Common Stock trade on?

Indivior Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Indivior Pharmaceuticals, Inc. - Common Stock is INDV on the Nasdaq Stock Market

What is the current price of Indivior Pharmaceuticals, Inc. - Common Stock?

The current price of Indivior Pharmaceuticals, Inc. - Common Stock is 38.82

When was Indivior Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Indivior Pharmaceuticals, Inc. - Common Stock was at 08/07/26 04:00 PM ET

What is the market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Indivior Pharmaceuticals, Inc. - Common Stock is 4.97B

How many shares of Indivior Pharmaceuticals, Inc. - Common Stock are outstanding?

Indivior Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.